Last $87.02 USD
Change Today -0.10 / -0.11%
Volume 1.4M
MNK On Other Exchanges
Symbol
Exchange
New York
As of 8:04 PM 11/21/14 All times are local (Market data is delayed by at least 15 minutes).

mallinckrodt plc (MNK) Snapshot

Open
$87.76
Previous Close
$87.12
Day High
$87.76
Day Low
$86.30
52 Week High
11/5/14 - $95.74
52 Week Low
11/25/13 - $49.08
Market Cap
9.9B
Average Volume 10 Days
1.8M
EPS TTM
$1.31
Shares Outstanding
113.7M
EX-Date
--
P/E TM
66.7x
Dividend
--
Dividend Yield
--
Current Stock Chart for MALLINCKRODT PLC (MNK)

mallinckrodt plc (MNK) Related Businessweek News

View More BusinessWeek News

mallinckrodt plc (MNK) Details

Mallinckrodt public limited company develops, manufactures, markets, and distributes branded and generic specialty pharmaceuticals, active pharmaceutical ingredients (API), and diagnostic imaging agents worldwide. The company’s Specialty Pharmaceuticals segment offers EXALGO extended-release tablets to treat chronic pain in opioid-tolerant patients; and GABLOFEN injections indicated for use in the management of spasticity of cerebral or spinal origin in patients age four years and above. This segment also provides generic pharmaceutical products, including acetaminophen products, oxycodone-containing tablets, hydrocodone-containing tablets, and methylphenidate HCl extended-release tablets USP (CII) to treat attention deficit hyperactivity disorder and addiction, as well as API products comprising hydrocodone and oxycodone; and medicinal opioids and synthetic controlled substances. This segment markets its branded products to physicians, including pain specialists, anesthesiologists, orthopedic surgeons, managed care organizations, and neurologists directly; and generic products to wholesalers, retail pharmacy chains, food store chains with pharmacies, mail order pharmacies, and hospital buying groups. Its Global Medical Imaging segment provides contrast media and delivery systems comprising ioversol and gadoversetamide injections for diagnostic imaging applications, such as computed tomography and magnetic resonance imaging under the Optiray and Optimark brands; and pre-filled syringes and proprietary power injectors. This segment also offers nuclear imaging agents consisting of technetium-99m generators under the Ultra-Technekow DTE brand; cold kits; and radiopharmaceuticals, such as Octreoscan kits for localization of tumors. This segment sells its contrast media systems to hospitals and imaging centers; and API products to other pharmaceutical companies directly or through distributors. The company is based in Dublin, Ireland.

mallinckrodt plc (MNK) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $823.9K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $380.6K
Chief Human Resources Officer and Senior Vice...
Total Annual Compensation: $433.3K
Senior Vice President and General Counsel
Total Annual Compensation: $367.4K
Compensation as of Fiscal Year 2013.

mallinckrodt plc (MNK) Key Developments

Mallinckrodt Public Limited Company Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended September 26, 2014; Reports Non-Restructuring Impairment Charges for the Fourth Quarter of 2014

Mallinckrodt public limited company reported unaudited consolidated earnings results for the fourth quarter and year ended September 26, 2014. For the quarter, the company’s net sales were $789.3 million for the fourth quarter of fiscal 2014 compared with $545.2 million reported in the fourth quarter of fiscal 2013, an increase of 44.8%. Strong net sales were driven by the inclusion and performance of H.P. Acthar Gel (Acthar) repository corticotropin injection and OFIRMEV (acetaminophen) injection, acquired in August 2014 and March 2014, respectively, and continuing strength in its base Specialty Controlled Substance Generics portfolio. Adjusted net income was $145.2 million, compared with $56.8 million a year ago. Non-GAAP adjusted diluted earnings per share were $1.68 against $0.98 a year ago, reflecting the accretive benefits of acquisitions and strong results in its Specialty Pharmaceuticals segment. Net loss was $352.4 million or $4.14 per diluted share compared with net income of $33.5 million or $0.58 per diluted share in the same period a year ago. The fiscal 2014 net loss reflects $355.6 million of non-cash impairment charges in the quarter primarily related to Global Medical Imaging segment goodwill and intangibles, and $75.1 million of restructuring charges. The company also incurred a $92.7 million increase in amortization and inventory fair value adjustment expenses from fiscal 2014 acquisitions, in addition to $30.0 million of transaction costs associated with the acquisition of Questcor Pharmaceuticals Inc. Operating loss was $356.5 million against operating income of $55.1 million a year ago. Loss from continuing operations before income taxes was $391.1 million against income from continuing operations before income taxes of $43.9 million a year ago. Loss from continuing operations was $352.4 million or $4.14 per diluted share against income from continuing operations of $31.2 million or $0.54 per diluted share a year ago. For the year, the company's net sales were $2.540 billion, compared with $2.205 billion in the prior year, representing a 15.2% increase. Adjusted net income was $324.8 million, compared with $180.7 million last year. Non-GAAP adjusted diluted earnings per share were $4.94, compared with $3.13 last year, an increase of 57.8%. This was attributable to the inclusion and performance of Acthar and OFIRMEV, strength in the base Specialty Controlled Substance Generics portfolio, ongoing restructuring to lower the company's overall cost base, and lower tax provision expense. These factors were partially offset by higher cost of goods sold experienced in the Global Medical Imaging segment and higher interest expense in fiscal year 2014. Operating loss was $284.1 million against operating income of $144.8 million a year ago. Loss from continuing operations before income taxes was $363.4 million against income from continuing operations before income taxes of $126.4 million a year ago. Loss from continuing operations was $318.6 million or $4.91 per diluted share against income from continuing operations of $57.8 million or $1.00 per diluted share a year ago. Net loss was $319.3 million or $4.92 per diluted share against net income of $58.8 million or $1.02 per diluted share a year ago. Net loss reflects $355.6 million of non-cash impairment charges primarily related to Global Medical Imaging segment goodwill and intangibles and $128.6 million of restructuring charges. For the fourth quarter of 2014, the company reported non-restructuring impairment charges of $355.6 million.

Mallinckrodt plc Responds to FDA's Expected Reclassification of Methylphenidate ER

Mallinckrodt plc has been informed by the U.S. Food and Drug Administration (FDA) that the agency has reason to believe that the company's methylphenidate hydrochloride extended-release (ER) tablets, USP (CII) may not be therapeutically equivalent to the category reference drug Concerta(R). As a result, the agency indicated that it has reclassified Mallinckrodt's ANDA 202608 for methylphenidate ER dosage strengths of 27mg, 36 mg and 54 mg from AB (freely substitutable at the pharmacy level) to BX (presumed to be therapeutically inequivalent). The agency announced that this change was based on the application of its new Draft Guidance for determining bioequivalence of methylphenidate hydrochloride products just published on November 6, 2014. Although the Draft Guidance has an open comment period through January 5, 2015, the agency nevertheless confirmed that this change would be reflected on November 13, 2014 in the on-line Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Mallinckrodt strongly believes its methylphenidate ER products are safe and effective when used in accordance with the approved labels.

Mallinckrodt public limited company to Report Q4, 2014 Results on Nov 19, 2014

Mallinckrodt public limited company announced that they will report Q4, 2014 results at 8:30 AM, US Eastern Standard Time on Nov 19, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MNK:US $87.02 USD -0.10

MNK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Endo International PLC $70.20 USD +0.445
Guerbet €34.83 EUR -0.33
Hospira Inc $58.82 USD +0.29
Lannett Co Inc $45.53 USD -1.02
Perrigo Co PLC $154.50 USD +0.23
View Industry Companies
 

Industry Analysis

MNK

Industry Average

Valuation MNK Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.9x
Price/Book 1.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MALLINCKRODT PLC, please visit www.mallinckrodt.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.